Post-earnings recap
Reported
Thu, Apr 25, 2024
Est. EPS
—
Est. revenue
—
Implied move
—
EPS beat rate
88%
—
Est. EPS
—
Est. Rev
—
Impl. Move
—
Edwards Lifesciences reported a slight EPS beat, which is a positive sign for the company. However, the stock reacted negatively, declining by 0.68%. Investors may be concerned about the lack of revenue data and forward guidance, which could indicate uncertainty about future performance.
| Metric | Actual | Expected | Surprise |
|---|---|---|---|
| EPS | $0.66 | N/A | +2.64% |
| Revenue | N/A | N/A | N/A |
Management expressed satisfaction with the EPS results, highlighting their commitment to growth. However, they did not provide specific guidance for future performance.
We are pleased with our EPS performance this quarter.
While we did not provide guidance, we remain focused on our long-term growth strategies.